(Press-News.org) PHILADELPHIA - A Penn Medicine patient with a genetic form of childhood blindness gained vision, which lasted more than a year, after receiving a single injection of an experimental RNA therapy into the eye. The clinical trial was conducted by researchers at the Scheie Eye Institute in the Perelman School of Medicine at the University of Pennsylvania. Results of the case, detailed in a paper published today in Nature Medicine, show that the treatment led to marked changes at the fovea, the most important locus of human central vision.
The treatment was designed for patients diagnosed with Leber congenital amaurosis (LCA) -- an eye disorder that primarily affects the retina -- who have a CEP290 mutation, which is one of the more commonly implicated genes in patients with the disease. Patients with this form of LCA suffer from severe visual impairment, typically beginning in infancy.
"Our results set a new standard of what biological improvements are possible with antisense oligonucleotide therapy in LCA caused by CEP290 mutations," said co-lead author Artur V. Cideciyan, PhD, a research professor of Ophthalmology. "Importantly, we established a comparator for currently-ongoing gene editing therapies for the same disease, which will allow comparison of the relative merits of two different interventions."
In an international clinical trial led at Penn Medicine by Cideciyan and Samuel G. Jacobson, MD, PhD, a professor of Ophthalmology, participants received an intraocular injection of an antisense oligonucleotide called sepofarsen. This short RNA molecule works by increasing normal CEP290 protein levels in the eye's photoreceptors and improving retinal function under day vision conditions.
In a 2019 study published in Nature Medicine, Cideciyan, Jacobson, and collaborators found that injections of sepofarsen repeated every three months resulted in continued vision gains in 10 patients. The eleventh patient, whose treatment was detailed in the latest Nature Medicine paper, received only one injection and was examined over a 15-month period. Prior to treatment, the patient had reduced visual acuity, small visual fields, and no night vision. After the initial dose, the patient decided to forgo the quarterly maintenance doses, because the regular dosing could lead to cataracts.
After a single injection of sepofarsen, more than a dozen measurements of visual function and retinal structure showed large improvements supporting a biological effect from the treatment. A key finding from the case was that this biological effect was relatively slow in uptake. The researchers saw vision improvement after one month, but the patient's vision reached a peak effect after month two. Most striking, the improvements remained when tested over 15 months after the first and only injection.
According to the researchers, the extended durability of vision improvement was unexpected and provides implications for treating other ciliopathies -- the name of the large category of diseases associated with genetic mutations encoding defective proteins, which results in the abnormal function of cilia, a protruding sensory organelle found on cells.
"This work represents a really exciting direction for RNA antisense therapy. It's been 30 years since there were new drugs using RNA antisense oligonucleotides, even though everybody realized that there was great promise for these treatments," said Jacobson. "The unexpected stability of the ciliary transition zone noted in the patient prompts reconsideration of dosing schedules for sepofarsen, as well as other cilium-targeted therapies."
One reason why antisense oligonucleotide has proven successful in treating this rare disease, according to the researchers, is that these tiny RNA molecules are small enough to get into the cell nucleus, but are not cleared very quickly, so they remain long enough to do their work.
"There are now, at least in the eye field, a series of clinical trials using antisense oligonucleotides for different genetic defects spawned by the success of the work in CEP290-associated LCA from Drs. Cideciyan and Jacobson," said Joan O'Brien, MD, chair of Ophthalmology in the Perelman School of Medicine and director of the Scheie Eye Institute
For future studies, the Penn authors are planning gene-specific therapies for other currently incurable blinding inherited retinal disorders.
INFORMATION:
Additional Penn authors included: Alexandra V. Garafalo, Alejandro J. Roman, Alexander Sumaroka, Arun K. Krishnan, and Malgorzata Swider.
The trial is being funded by ProQR Therapeutics with additional support from the National Institutes of Health.
What The Article Says: This JAMA Insights Clinical Update from the CDC's COVID-19 Response Team discusses the association of changes in COVID-19 case rates and death rates with implementation of state-issued mask mandates and allowance of any on-premises restaurant dining.
Authors: Gery P. Guy Jr, Ph.D., M.P.H., of the Centers for Disease Control and Prevention in Atlanta, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2021.5455)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding ...
UConn researcher Paulo Verardi, associate professor of pathobiology and veterinary science in the College of Agriculture, Health and Natural Resources, has demonstrated the success of a vaccine against Zika virus and recently published his findings in END ...
DARIEN, IL - The American Academy of Sleep Medicine recently published an update on the use of telemedicine for the diagnosis and treatment of sleep disorders to reflect lessons learned from the transition to telemedicine during the COVID-19 pandemic and the benefits of continuing to utilize remote care when appropriate.
While the technology to remotely connect doctor and patient has been in place for years, its use was limited until the spread of COVID-19. In 2020, the Centers for Medicare & Medicaid Services (CMS) lifted restrictions on telemedicine reimbursement, and private insurance companies followed suit. Telemedicine ...
When we watch a mime seemingly pull rope, climb steps or try to escape that infernal box, we don't struggle to recognize the implied objects -- our minds automatically "see" them, a new study concludes.
To explore how the mind processes the objects mimes seem to interact with, Johns Hopkins University cognitive scientists brought the art of miming into the lab, concluding that invisible, implied surfaces are represented rapidly and automatically. The work appears today in the journal Psychological Science.
"Most of the time, we know which objects are ...
In the 1960s, a national focus on hunger was essential to address major problems of undernutrition after World War II. In the 1990s, the nation shifted away from hunger toward "food insecurity" to better capture and address the challenges of food access and affordability.
Now, a END ...
Space scientists at the University of Bath in the UK have found a new way to probe the internal structure of neutron stars, giving nuclear physicists a novel tool for studying the structures that make up matter at an atomic level.
Neutron stars are dead stars that have been compressed by gravity to the size of small cities. They contain the most extreme matter in the universe, meaning they are the densest objects in existence (for comparison, if Earth were compressed to the density of a neutron star, it would measure just a few hundred meters in diameter, and all humans would fit in a teaspoon). This makes neutron stars unique natural laboratories ...
Recent research from the University of Vaasa and the University of Jyväskyla shows that speculation and lottery-like behavior is a fundamental factor for the pricing of cryptocurrencies. Speculation could explain the enormous increase in the market capitalizations of cryptocurrencies.
Nowadays more than 8000 cryptocurrencies have been launched. Unlike traditional assets like stocks, research has shown that investments in cryptocurrencies are associated with a considerably higher level of uncertainty. The price of Bitcoin, which is the first traded cryptocurrency, increased by from $7,200.17 to $29,374.15 in January 1, 2020 ...
A team of researchers at the University of Alberta has uncovered a long-sought link in the battle to control cholesterol and heart disease.
The protein that interferes with low-density lipoprotein (LDL) receptors that clear "bad" cholesterol from the blood was identified in END ...
MADISON - Bipolar disorder affects millions of Americans, causing dramatic swings in mood and, in some people, additional effects such as memory problems.
While bipolar disorder is linked to many genes, each one making small contributions to the disease, scientists don't know just how those genes ultimately give rise to the disorder's effects.
However, in new research, scientists at the University of Wisconsin-Madison have found for the first time that disruptions to a particular protein called Akt can lead to the brain changes characteristic of bipolar disorder. The results offer a foundation for research into treating the often-overlooked cognitive impairments of bipolar disorder, ...
NASA's OSIRIS-REx mission is on the brink of discovering the extent of the mess it made on asteroid Bennu's surface during last fall's sample collection event. On Apr. 7, the OSIRIS-REx spacecraft will get one last close encounter with Bennu as it performs a final flyover to capture images of the asteroid's surface. While performing the flyover, the spacecraft will observe Bennu from a distance of about 2.3 miles (3.7 km) - the closest it's been since the Touch-and-Go Sample Collection event on Oct. 20, 2020.
The OSIRIS-REx team decided to add this last flyover after Bennu's surface was significantly disturbed by the sample collection event. During touchdown, the spacecraft's ...
